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Abstract

Pheochromocytoma is a neuroendocrine tumor characterized by the excessive
production of catecholamines (epinephrine, norepinephrine, and dopamine). The diagnosis
is suspected due to hypertensive paroxysms, associated with vegetative phenomena, due
to the catecholaminergic hypersecretion. Diagnosis involves biochemical tests that reveal
elevated levels of catecholamine metabolites (metanephrine and normetanephrine).
Functional imaging, such as 123I-metaiodobenzylguanidine scintigraphy (123I-MIBG),
has increased specificity in identifying the catecholamine-producing tumor and its
metastases. The gold-standard treatment for patients with pheochromocytoma is
represented by the surgical removal of the tumor. Before surgical resection, it is important
to optimize blood pressure and intravascular volume in order to avoid negative
hemodynamic events.
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Highlights

✓ The gold-standard treatment in patients diagnosed with pheochromocytoma is the surgical
removal of the tumor. Preoperative preparation is very important and its goal is to decrease
the incidence of intraoperative cardiovascular complications.

catecholamines, hypertensive paroxysm, metanephrine, normetanephrine, alpha-receptors
blockade

✓ The incidence of morbidity and mortality associated with the surgical removal of these
tumors has decreased recently, considering the careful and prompt management in the
perioperative period and the advancements of the surgical technique.
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Introduction
Pheochromocytoma is a neuroendocrine tumor derived
from the chromaffin cells of the medullary portion of the
adrenal glands, being characterized by the excessive
production and release of catecholamines (adrenaline and
noradrenaline) (1). Paraganglioma is also a catecholamine
producing tumor, but with extra-adrenal localization (2).
The most important clinical manifestation of
pheochromocytoma is the hypertensive crisis due to the
tumoral secretion of catecholamines (1). Surgical removal
of the tumor represents the treatment of choice in order to
cure and prevent cardiovascular complications (3).

Discussions
Epidemiology and etiology
Pheochromocytoma occurs with equal frequency in
men and women, and it can occur at any age (4). In 20%
of the cases, pheochromocytoma has a hereditary
transmission, with bilateral localization (3). 10% of the
cases of pheochromocytoma are malignant, and
paraganglioma occurs in 10-15% of the cases (5). A genetic
component has been identified in 30% of the cases of
pheochromocytoma, being associated with Von HippelLindau disease, with neurofibromatosis, and with multiple
endocrine neoplasia type 1 and type II syndrome (MEN I
and MEN II) (6). The etiology of pheochromocytoma is
represented by increased tumoral production and the
secretion of catecholamines (4).
Pathophysiology
The pathophysiological mechanism underlying
pheochromocytoma is represented by the increased release
of catecholamine hormones, secreted by the tumor,
continuously or in an episodic manner. These hormones,
which include epinephrine, norepinephrine, and dopamine,
excessively stimulate alpha- and beta-adrenergic receptors,
with all the clinical manifestations in pheochromocytoma
being related to this (7).
The symptomatology in pheochromocytoma is given
by the predominant type of catecholaminergic secretion.
Epinephrine stimulates beta-1 and beta-2 adrenergic
receptors. By stimulating beta-2 adrenergic receptors,
epinephrine causes vasodilation in striate muscles. Also,
epinephrine has metabolic effects, stimulating hepatic
glycogenolysis and gluconeogenesis, thus leading to
hyperglycemia (8). Norepinephrine stimulates alpha-1,
alpha-2, and beta-2 adrenergic receptors, leading to
vasoconstriction and increased blood pressure.
Epinephrine and norepinephrine have positive
chronotropic effects through their action on beta-1
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adrenergic receptors (9). Dopamine stimulates
dopaminergic receptors D1 and D2. In cases of
pheochromocytoma, dopamine concentrations are
elevated, thus causing vasoconstriction and increased heart
rate (10). Moreover, pheochromocytoma is characterized
by the release of other substances, such as neuron-specific
enolase,
vasoactive
intestinal
peptide,
or
adrenocorticotropic hormone (ACTH), which cause
various other clinical manifestations (9).
Clinical presentation
The classical manifestation in pheochromocytoma is
represented by the hypertensive crisis, associated with
palpitations and diaphoresis, these symptoms being the
result of the massive release of catecholaminergic
hormones from the tumor. This symptomatology is present
in 40% of the patients with pheochromocytoma (11). The
hypertensive paroxysm can be triggered by different type
of stress, such as surgery or anesthetics, intense physical
effort, smoking, or palpation of the lumbar region (12).
The hypertensive crisis may last from a few minutes to
a few hours. The end of the hypertensive paroxysm is
characterized by arterial hypotension. The crisis is also
associated with various symptoms, such as headache,
diaphoresis, and heart rhythm disorders, these
manifestations supporting the positive diagnosis of
pheochromocytoma. Also, anxiety, visual disturbances,
nausea, chest pain, or abdominal pain are associated with
hypertensive paroxysm (13).
The effects of severe hypertension are quantified in
lesions of the end-organs, especially the heart, kidney,
eyes, and central nervous system. Also, hypertensive
paroxysm can be associated with the signs and symptoms
of hypertensive encephalopathy (such as an altered state of
consciousness and convulsions) and acute myocardial
ischemia due to the increased oxygen demand (14). Other
clinical manifestations occur in pheochromocytoma due to
the release of neuropeptides. Thus, the hypersecretion of
ACTH leads to the occurrence of the signs and symptoms
of hypercorticism. Also, the hypersecretion of calcitonin
leads to hypocalcemia (15). Pheochromocytoma in genetic
syndromes can be associated with other clinical signs, such
as café-au-lait skin spots (13).
Diagnosis
When pheochromocytoma is suspected, the levels of
catecholamines and their metabolites should be tested, such
as metanephrines and normetanephrines. A rise in the
plasma levels of metanephrines is an indicator of increased
tumoral production and release of catecholamines. This
diagnostic test has both high sensitivity and specificity.
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Measurement of urinary metanephrines is also a test with
high sensitivity in the diagnosis of pheochromocytoma
(16). The measurement of plasmatic and urinary
vanillylmandelic acid (VMA) is a test used for the
diagnosis of these tumors (15).
Methoxytyramine is a marker used in the identification
of malignant forms of pheochromocytoma. Also,
chromogranin A is a marker of the presence of
neuroendocrine tumors (17). The imaging evaluation
(computed tomography [CT] and magnetic resonance
imaging [MRI]) is important in establishing the
localization and the dimensions of the tumor and also in
identifying metastatic lesions. MRI describes the
anatomical details and the vascular structures more clearly,
but it does not identify small dimension tumors (18).
Functional imaging using radiotracers such as 123Imetaiodobenzylguanidine scintigraphy (123I-MIBG) and
111In-DTPA-pentetreotide scintigraphy has increased
specificity in identifying the catecholamine-producing
tumors and their metastases (19). Also, genetic tests are
required in patients with a family history of
pheochromocytoma (17).
Preoperative preparation
Pheochromocytoma is associated with end-organ
lesions as a result of the excess of catecholamines. In this
context, the surgical removal of these tumors is
recommended in order to cure and prevent the lesions. Chai
et al. observed that in patients diagnosed with
pheochromocytoma, open transperitoneal adrenalectomy is
the gold standard treatment (18). Nevertheless, due to the
constant technological developments and also the need for
less invasive surgery, the laparoscopic approach has
become more popular over time. Before surgical resection,
it is important to optimize the blood pressure and the
intravascular volume as steps to avoid the negative
hemodynamic events during surgery (20).
The need for preoperative antihypertensive therapy has
been studied in patients with pheochromocytoma (21). In a
retrospective study by Pogorzelski et al. from 2006 – 2012
that
included
67
patients
diagnosed
with
pheochromocytoma, a regression of arterial hypertension
after surgical treatment of the tumor was noticed (22).
Recent evidence shows that preoperative preparation with
antihypertensive therapy decreases intra- and postoperative
cardiovascular complications (23). The Endocrine Society
Clinical
Guidelines
Subcommittee
recommends
preoperative alpha-blockade in patients undergoing the
resection of the pheochromocytoma (22).
Guidelines indicate that preoperative preparation for
the surgical removal of pheochromocytoma requires 5-15

days of the administration of alpha-receptor blockers and
methods to increase the intravascular volume (20). The
purpose of the preoperative preparation is to control the
blood pressure for at least 3-5 days, with a systolic blood
pressure under 130 mmHg and a diastolic value under 80
mmHg24.
The main cause of hypertension in patients with
pheochromocytoma is the alpha-receptor activation due to
the excess of catecholamines. In this context, the first line
therapy is represented by alpha-receptor antagonists. Also,
beta-receptor antagonists and calcium channel blockers are
used (25).
Prazosin, doxazosin, and terazosin are selective alpha1 receptor antagonists. These drugs act on the alpha-1
receptors and produce vasodilation. The antagonism
produced by these drugs is reversible (24). Prazosin is most
frequently used in patients with indications of surgical
resection of pheochromocytoma. Doses of prazosin are
gradually increased, depending on the hypotensive
response of the patient. Studies revealed a good
perioperative control and adequate alpha-blockade in
patients with pheochromocytoma (26). Doxazosin and
terazosin are alternatives to prazosin, which is most
commonly used.
Beta-blockers should not be administered before the
initiation of alpha-receptor antagonists because the
antagonism of beta-receptors can lead to acute cardiac
failure and pulmonary edema. Beta-blockers are
administered only after the initiation of alpha-receptor
blockers (22). Cardio selective beta-blockers are more
frequently used because this class has fewer side-effects.
The most commonly used beta-receptor antagonists in
patients with pheochromocytoma with indication for
resection are metoprolol, atenolol, bisoprolol, carvedilol,
propranolol (which is a non-selective beta-blocker), and
labetalol. Labetalol has effects of alpha- and beta-receptor
antagonism (27).
Calcium channel blockers can be administered as
primary drugs in order to control hypertension or as adjunct
antihypertensive therapy. Guidelines recommend these
drugs especially for the control of blood pressure in
patients with hypertensive paroxysms (23). The most
commonly used calcium channel blockers are amlodipine,
nicardipine, nifedipine, verapamil, and diltiazem (28).
Goldstein et al. highlighted the importance of alphablockade in patients diagnosed with pheochromocytoma
with indication for the surgical removal of the tumor. They
found 69% of the patients without alpha-blockade
experienced perioperative cardiovascular complications,
compared to 3% of the patients who received alpha-
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blockers and did not experience intraoperative
cardiovascular complications (26). Because the
administration of alpha-receptor blockers can cause severe
orthostatic hypotension, increasing intravascular volume
with intravenous crystalloids and colloids is recommended
(25).
Intraoperative drugs used in cases of hypertensive
paroxysm are sodium nitroprusside and nitroglycerine
(28). Also, esmolol is a beta-receptor blocker used
intraoperatively to control hypertension and tachycardia
(29). Intraoperative hypertension and hemodynamic
instability occur depending on anesthetic drugs, tumoral
dimensions, and plasma catecholamine levels (30).
Many studies report that postoperative hypotension has
an incidence of 20-70% and is associated with the
administration of the alpha-receptor antagonists before
surgery and hypotensive agents administered during the
surgical intervention (31, 32). Also, hyperinsulinemia and
hypoglycemia may be noticed after the removal of the
tumor.
After the surgical resection of the tumor, the values of
blood pressure will normalize. Also, the values of the
catecholamine metabolites will be within normal limits.
Guidelines recommend that postoperative follow-up
should occur through a three-month assessment period
(33).

Conclusions
The clinical manifestations of pheochromocytoma may
vary. The classical manifestation is represented by
hypertensive paroxysm, associated with a vegetative
phenomenon, such as palpitations or diaphoresis. CT scans
represent the best functional imaging tests. Also, MRI
scans may be used in cases of metastases or when radiation
is to be avoided.
The gold-standard treatment in patients diagnosed with
pheochromocytoma is the surgical removal of the tumor.
Preoperative preparation is very important and its goal is to
decrease the incidence of intraoperative cardiovascular
complications. The first-line treatment is represented by
alpha-receptor antagonists, especially selective ones
(alpha-1 receptor antagonists). Also, beta-receptor
antagonists and calcium channel blockers are used as
adjunct antihypertensive therapy. The vascular volume
replacement with fluids administered intravenously is
recommended to avoid hypotension, which is the most
common complication after tumor removal. The incidence
of morbidity and mortality associated with the surgical
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removal of these tumors has decreased recently,
considering the careful and prompt management in the
perioperative period and the advancements of the surgical
technique.
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